Prothena Corp. plc Stock
Price
Target price
€7.90
€7.90
2.090%
0.158
2.090%
€16.28
10.08.26 / Tradegate
WKN: A1KAVV / Symbol: PRTA / Name: Prothena Corp / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Prothena Corp. plc Stock
Prothena Corp. plc gained 2.090% today.
Prothena Corp. plc is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
Based on the current price of 7.9 € the target price of 16 € shows a potential of 102.48% for Prothena Corp. plc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Prothena Corp. plc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Prothena Corp. plc in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Prothena Corp. plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Prothena Corp. plc | 2.090% | 9.385% | -2.469% | 19.727% | -3.634% | -85.889% | -84.069% |
| Heron Therapeutics Inc. | -3.700% | -36.899% | -25.120% | -74.449% | -74.794% | -81.154% | -97.132% |
| Evolus Inc | 1.380% | 22.760% | 11.689% | 29.317% | 18.165% | -27.640% | -28.840% |
| Rhythm Pharmaceuticals | -1.030% | 7.065% | 3.684% | 26.282% | 5.348% | 303.689% | 764.035% |
Comments
Prothena (PRTA) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for PRTA provided by MarketBeat
Prothena (PRTA) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for PRTA provided by MarketBeat
Prothena (PRTA) had its "outperform" rating reaffirmed by Citigroup Inc..
Show more
Ratings data for PRTA provided by MarketBeat